​

Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TVTX Stock Forecast

Travere Therapeutics (TVTX) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $35.00, with a high of $35.00 and a low of $35.00. This represents a -1.24% decline from the last price of $35.44.

$5 $12 $19 $26 $33 $40 High: $35 Avg: $35 Low: $35 Last Closed Price: $35.44

TVTX Stock Rating

Travere Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (83.33%), 3 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 3 15 Strong Sell Sell Hold Buy Strong Buy

TVTX Price Target Upside V Benchmarks

TypeNameUpside
StockTravere Therapeutics-1.24%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$35.00$35.00
Last Closing Price$35.44$35.44$35.44
Upside/Downside--1.24%-1.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 252112--15
Oct, 252112--15
Sep, 252112--15
Aug, 253112--16
Jul, 253112--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2025Maury RaycroftJefferies$35.00$27.3128.16%-1.24%
Oct 31, 2024Liisa BaykoEvercore ISI$33.00$17.5088.57%-6.88%
Oct 21, 2024Mohit BansalWells Fargo$27.00$17.8751.09%-23.81%
Oct 10, 2024Liisa BaykoEvercore ISI$30.00$18.0766.02%-15.35%
Oct 09, 2024Jason ZemanskyBank of America Securities$20.00$15.2131.49%-43.57%
Oct 01, 2024Carter GouldBarclays$18.00$13.9928.66%-49.21%
Sep 27, 2024Vamil DivanGuggenheim$23.00$15.0452.93%-35.10%
Sep 27, 2024Ed ArceH.C. Wainwright$18.00$15.0419.68%-49.21%
Sep 27, 2024Greg HarrisonBank of America Securities$18.00$14.0128.48%-49.21%
Sep 10, 2024Ed NashCanaccord Genuity$23.00$12.7081.10%-35.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2025Piper SandlerNeutralNeutralhold
Oct 31, 2025CitigroupBuyBuyhold
Oct 31, 2025Cowen & Co.BuyBuyhold
Sep 11, 2025Wells FargoOverweightOverweighthold
Aug 28, 2025H.C. WainwrightBuyBuyhold
Aug 10, 2025CitigroupBuyBuyhold
Aug 07, 2025ScotiabankOutperformOutperformhold
May 16, 2025CitigroupBuyBuyhold
Apr 11, 2025ScotiabankOutperformOutperformhold
Jan 29, 2025Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.56$-3.01$-4.37$-1.50$-4.08----
Avg Forecast$-1.45$-3.01$-4.48$-1.62$-3.66$-1.13$0.60$1.11$1.88
High Forecast$-1.08$-2.24$-3.17$-1.39$-3.54$-0.39$2.59$3.24$2.67
Low Forecast$-2.20$-4.59$-6.86$-1.79$-3.82$-1.75$-0.64$0.40$0.70
Surprise %145.52%--2.46%-7.41%11.48%----

Revenue Forecast

$100M $290M $480M $670M $860M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$198.32M$227.49M$212.02M$145.24M$233.18M----
Avg Forecast$198.95M$225.72M$208.36M$195.51M$230.58M$342.48M$478.46M$630.10M$780.85M
High Forecast$279.02M$316.57M$293.80M$198.06M$243.97M$415.94M$488.58M$833.66M$1.03B
Low Forecast$159.94M$181.47M$161.65M$193.14M$220.79M$266.55M$468.34M$325.75M$403.68M
Surprise %-0.31%0.78%1.76%-25.71%1.13%----

Net Income Forecast

$-500M $-350M $-200M $-50M $100M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-169.43M$-180.09M$-278.48M$-111.40M$-321.55M----
Avg Forecast$-107.37M$-142.95M$-176.32M$-376.33M$-273.28M$-113.69M$41.94M$117.12M$139.77M
High Forecast$-80.01M$-114.36M$-141.05M$-301.07M$-262.54M$-29.06M$191.99M$240.53M$198.47M
Low Forecast$-163.55M$-171.54M$-211.58M$-451.60M$-284.02M$-129.88M$-47.47M$29.42M$52.01M
Surprise %57.80%25.98%57.94%-70.40%17.66%----

TVTX Forecast FAQ

Is Travere Therapeutics stock a buy?

Travere Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Travere Therapeutics is a favorable investment for most analysts.

What is Travere Therapeutics's price target?

Travere Therapeutics's price target, set by 18 Wall Street analysts, averages $35 over the next 12 months. The price target range spans from $35 at the low end to $35 at the high end, suggesting a potential -1.24% change from the previous closing price of $35.44.

How does Travere Therapeutics stock forecast compare to its benchmarks?

Travere Therapeutics's stock forecast shows a -1.24% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Travere Therapeutics over the past three months?

  • November 2025: 13.33% Strong Buy, 73.33% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 13.33% Strong Buy, 73.33% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 13.33% Strong Buy, 73.33% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.

What is Travere Therapeutics’s EPS forecast?

Travere Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.13, marking a -72.30% decrease from the reported $-4.08 in 2024. Estimates for the following years are $0.6 in 2026, $1.11 in 2027, and $1.88 in 2028.

What is Travere Therapeutics’s revenue forecast?

Travere Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $342.48M, reflecting a 46.88% increase from the reported $233.18M in 2024. The forecast for 2026 is $478.46M, followed by $630.1M for 2027, and $780.85M for 2028.

What is Travere Therapeutics’s net income forecast?

Travere Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-114M, representing a -64.64% decrease from the reported $-322M in 2024. Projections indicate $41.94M in 2026, $117.12M in 2027, and $139.77M in 2028.